Brokerages Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) Price Target at $9.56

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have been given a consensus rating of “Hold” by the thirteen ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $9.56.

A number of equities research analysts have commented on the company. Stifel Nicolaus reissued a “hold” rating and issued a $2.00 price objective (down previously from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th. Wells Fargo & Company decreased their price target on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. JPMorgan Chase & Co. lowered shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. HC Wainwright raised shares of RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Thursday, December 26th. Finally, Piper Sandler lowered shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $8.00 to $2.00 in a report on Monday, November 11th.

RAPT Therapeutics Stock Performance

RAPT Therapeutics stock opened at $1.11 on Wednesday. The stock has a market capitalization of $38.81 million, a price-to-earnings ratio of -0.40 and a beta of 0.03. RAPT Therapeutics has a 52-week low of $0.79 and a 52-week high of $27.35. The stock’s 50 day moving average price is $1.26 and its two-hundred day moving average price is $1.81.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. On average, equities research analysts forecast that RAPT Therapeutics will post -2.43 EPS for the current year.

Hedge Funds Weigh In On RAPT Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Readystate Asset Management LP purchased a new stake in shares of RAPT Therapeutics during the third quarter valued at approximately $36,000. Los Angeles Capital Management LLC grew its stake in RAPT Therapeutics by 9.2% in the 4th quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company’s stock valued at $348,000 after purchasing an additional 18,558 shares during the period. JPMorgan Chase & Co. increased its position in shares of RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after purchasing an additional 25,130 shares during the last quarter. Barclays PLC raised its stake in shares of RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after purchasing an additional 29,195 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of RAPT Therapeutics in the 2nd quarter worth about $108,000. Hedge funds and other institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.